

Title (en)
\$(EX VIVO) TREATMENT OF ALLOGENEIC AND XENOGENEIC T-CELLS WITH gp39 ANTAGONISTS

Title (de)
EX VIVO BEHANDLUNG VON ALLOGENEN UND XENOGENEN T-ZELLEN MIT GP39-ANTAGONISTEN

Title (fr)
TRAITEMENT \$(EX VIVO) DE LYMPHOCYTES T ALLOGENIQUES ET XENOGENIQUES A L'AIDE D'ANTAGONISTES DE gp39

Publication
EP 1100515 A4 20030402 (EN)

Application
EP 99944997 A 19990729

Priority
• US 9916686 W 19990729
• US 12468398 A 19980730

Abstract (en)
[origin: WO0006178A1] Methods for inducing T-cell non-responsiveness to donor T-cells comprised in transplantation tissues are provided. The methods involve ex vivo treatment of donor T-cells with gp39 antagonists.

IPC 1-7
A61K 35/14; **A61K 39/395**; **C12N 5/06**; **A61P 37/06**

IPC 8 full level
A61K 39/00 (2006.01); **A61K 39/395** (2006.01); **A61P 35/00** (2006.01); **A61P 37/00** (2006.01); **C07K 16/28** (2006.01); **C12N 5/02** (2006.01); **C12N 5/0783** (2010.01); **A61K 35/12** (2015.01)

CPC (source: EP KR US)
A61K 39/001 (2013.01 - EP US); **A61K 39/4611** (2023.05 - EP KR); **A61K 39/4621** (2023.05 - EP KR); **A61K 39/46434** (2023.05 - EP KR); **A61K 39/464411** (2023.05 - EP KR); **A61P 35/00** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 37/06** (2018.01 - EP); **C07K 16/2875** (2013.01 - EP US); **C12N 5/0636** (2013.01 - EP KR US); **A61K 2035/122** (2013.01 - EP US); **A61K 2035/124** (2013.01 - EP US); **A61K 2039/5158** (2013.01 - US); **A61K 2239/38** (2023.05 - EP KR); **C12N 2501/52** (2013.01 - EP US)

Citation (search report)
• [Y] US 5683693 A 19971104 - NOELLE RANDOLPH J [US], et al
• [Y] WO 9734633 A1 19970925 - BRISTOL MYERS SQUIBB CO [US]
• [X] BLAZAR B R ET AL: "Ex vivo induction of donor anti-host alloantigen hyporesponsiveness by targeting CD40 ligand (CD40L) on donor CD4+ T cells prevents GVHD lethality in vivo.", BLOOD, vol. 90, no. 10 SUPPL. 1 PART 1, 15 November 1997 (1997-11-15), 39th Annual Meeting of the American Society of Hematology; San Diego, California, USA; December 5-9, 1997, pages 205A, XP002229015, ISSN: 0006-4971
• [PX] BLAZAR BRUCE R ET AL: "CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 102, no. 3, 1 August 1998 (1998-08-01), pages 473 - 482, XP002187718, ISSN: 0021-9738
• [Y] GRIBBEN J G ET AL: "COMPLETE BLOCKADE OF B7 FAMILY-MEDIATED COSTIMULATION IS NECESSARY TO INDUCE HUMAN ALLOANTIGEN-SPECIFIC ANERGY: A METHOD TO AMELIORATE GRAFT-VERSUS-HOST DISEASE AND EXTEND THE DONOR POOL", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 87, no. 11, 1 June 1996 (1996-06-01), pages 4887 - 4893, XP001027675, ISSN: 0006-4971
• [T] MURPHY W J ET AL: "New strategies for preventing graft-versus-host disease", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 11, no. 5, 1 October 1999 (1999-10-01), pages 509 - 515, XP004257577, ISSN: 0952-7915
• See also references of WO 0006178A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0006178 A1 20000210; AT E309808 T1 20051215; AU 5770399 A 20000221; AU 764015 B2 20030807; AU 764015 C 20060316; CA 2338773 A1 20000210; CN 1161129 C 20040811; CN 1319019 A 20011024; DE 69928407 D1 20051222; DE 69928407 T2 20060803; DK 1100515 T3 20051212; EP 1100515 A1 20010523; EP 1100515 A4 20030402; EP 1100515 B1 20051116; EP 1637146 A2 20060322; EP 1637146 A3 20080220; ES 2252970 T3 20060516; HU P0103107 A2 20011128; JP 2002521042 A 20020716; JP 4109828 B2 20080702; KR 100711210 B1 20070424; KR 20010071078 A 20010728; NO 20010488 D0 20010129; NO 20010488 L 20010327; US 2002022020 A1 20020221; US 2002048579 A1 20020425

DOCDB simple family (application)
US 9916686 W 19990729; AT 99944997 T 19990729; AU 5770399 A 19990729; CA 2338773 A 19990729; CN 99811190 A 19990729; DE 69928407 T 19990729; DK 99944997 T 19990729; EP 05076853 A 19990729; EP 99944997 A 19990729; ES 99944997 T 19990729; HU P0103107 A 19990729; JP 2000562032 A 19990729; KR 20017001308 A 20010130; NO 20010488 A 20010129; US 83512601 A 20010416; US 95153701 A 20010914